Benzinga | Nov 19, 2021 07:24AM EST

Morgan Stanley Downgrades Avrobio to Equal-Weight, Lowers Price Target to $7

Morgan Stanley analyst Michael Ulz downgrades Avrobio (NASDAQ:AVRO) from Overweight to Equal-Weight and lowers the price target from $24 to $7.